Search results
FDA Approves Pivya, a New Treatment for UTIs in Women
Health via Yahoo News· 16 hours agoIs Pivya—and How Effective Is it? Pivya is a synthetic version of penicillin that’s been used in...
Neuralink To Test Brain Implant On Second Patient - Slashdot
Slashdot· 1 hour agoThe FDA has approved Neuralink to implant its brain chip in a second patient. According to the Wall Street Journal, the company also outlined fixes to an ...
FDA Approves First Interchangeable Biosimilars to Aflibercept for AMD
MedPage Today· 1 day agoThe FDA approved the first interchangeable biosimilars to aflibercept (Eylea) to treat macular degeneration, according to an announcement from the agency ...
US FDA approves two biosimilars for blockbuster eye drug Eylea
Reuters via Yahoo News· 18 hours agoThe agency approved Biocon Biologics' Yesafili as well as Samsung Bioepis and Biogen's Opuviz, while...
FDA approves lung cancer treatment
CW39 NewsFix· 7 hours ago(KIAH) – Lung Cancer is a complex and devastating disease with over 200,000 new cases in 2024 alone. Small Cell Lung Cancer, or SCLC, is one of the most aggressive cancers out there, reportin…
One year after FDA approves over-the-counter birth control pill, advocates push for more access
Idaho Capital Sun via Yahoo News· 22 hours ago“My parents are immigrants from India, and it’s been over the counter there since my mom can...
FDA gives Neuralink another shot at brain chip – report
The Register· 11 hours agoAmerica's Food and Drug Administration (FDA) has reportedly approved Neuralink to implant an updated...
FDA Withdraws Approval of FGFR Inhibitor for Bile Duct Cancer
MedPage Today· 1 day agoThe FDA has withdrawn the approval of infigratinib (Truseltiq) as a second-line treatment for...
FDA approves Amgen drug for tough-to-treat form of lung cancer
BioPharma Dive via Yahoo Finance· 4 days agoImdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following...
FDA Approves Tarlatamab for Extensive-Stage SCLC
Medscape· 5 days agoContinued approval of the first-in-class bispecific T-cell engager (BiTE) may depend on proof of clinical benefit.